These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Responding to an FDA warning--geographic variation in the use of rosiglitazone. Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379 [No Abstract] [Full Text] [Related]
4. The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia. Habib AS; Gan TJ J Clin Anesth; 2008 Feb; 20(1):35-9. PubMed ID: 18346607 [TBL] [Abstract][Full Text] [Related]
5. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Olfson M; Marcus SC; Druss BG Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433 [TBL] [Abstract][Full Text] [Related]
6. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility. Matlock A; Allan N; Wills B; Kang C; Leikin JB Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886 [TBL] [Abstract][Full Text] [Related]
7. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians. Paschall S; Kaunitz AM Contraception; 2008 Nov; 78(5):370-6. PubMed ID: 18929733 [TBL] [Abstract][Full Text] [Related]
8. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. Murphy S; Roberts R J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581 [TBL] [Abstract][Full Text] [Related]
9. FDA response to droperidol black box warning editorials. Rappaport BA Anesth Analg; 2008 May; 106(5):1585. PubMed ID: 18420886 [No Abstract] [Full Text] [Related]
10. Is the FDA on drugs? Calabresi M; Park A Time; 2010 Aug; 176(8):24-8. PubMed ID: 20821962 [No Abstract] [Full Text] [Related]
11. The truth about rosiglitazone (avandia). Ledbetter C; Laustsen G Nurse Pract; 2008 Jun; 33(6):10-1. PubMed ID: 18528195 [No Abstract] [Full Text] [Related]
12. FDA needs more funding, NEJM says, amid questions about antidiabetes drug. Tanne JH BMJ; 2007 Aug; 335(7615):322. PubMed ID: 17703024 [No Abstract] [Full Text] [Related]
16. FDA boxed warnings: how to prescribe drugs safely. O'Connor NR Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888 [TBL] [Abstract][Full Text] [Related]
17. The black box warning. Abourjaily HM; Rosenberg M J Mass Dent Soc; 2002; 51(3):54-6. PubMed ID: 12380043 [No Abstract] [Full Text] [Related]
18. Black box warning for topical calcineurin inhibitors and the death of common sense. Fleischer AB Dermatol Online J; 2006 Oct; 12(6):2. PubMed ID: 17083882 [TBL] [Abstract][Full Text] [Related]
19. Revisiting the rosiglitazone story--lessons learned. Rosen CJ N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395 [No Abstract] [Full Text] [Related]
20. FDA committees say keep rosiglitazone available but increase warnings. Tanne JH BMJ; 2007 Aug; 335(7613):223. PubMed ID: 17673743 [No Abstract] [Full Text] [Related] [Next] [New Search]